Prognostic Values of Coronary Microvascular Dysfunction in Patients With Dilated Cardiomyopathy

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

About this trial

The goal of this observational study is to learn about the long-term prognostic of coronary microvascular dysfuction in Patients with Dilated Cardiomyopathy.

The main question it aims to answer is: Does the coronary microvascular dysfunction impact the outcomes in Patients with Dilated Cardiomyopathy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Dilated cardiomyopathy comfirmed by echocardiography: LVDd > 55 mm in men or > 50 mm in women.

Clinically evident congestive heart failure: Compatible symptoms and signs, and BNP ≥ 35 pg/mL or NT-proBNP ≥ 125 pg/mL, and LV systolic dysfunction defined by LVEF < 45 %.

Coronary angiography showing stenosis ≤ 50 % in all major epicardial vessels.

Disqualifiers

Patients with coronary artery disease, hypertensive heart disease, rheumatic valvular heart disease, myocarditis, and other secondary cardiomyopathies.

poor angiographic image quality

Trial population

Patients aged ≥ 18 years with angiography-confirmed absence of coronary stenosis and a definitive diagnosis of dilated cardiomyopathy.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • coronary angiography

    Procedure/Surgery

    Patients should undergo coronary angiography to confirm the absence of significant coronary stenosis. Angio-IMR was calculated based on the angiography.

Treatment groups

330 Participants
are divided into 2 treatment groups
Group A: Coronary microvascular dysfunction1 intervention
Group B: Non-Coronary microvascular dysfunction1 intervention

Trial outcomes

Primary outcomes

1

Major adverse cardiac events

A composite of cardiac death, hospitalization for heart failure, heart transplantation, and device implantation

Time frame
At 5-year follow-up

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.